Your browser is no longer supported. Please, upgrade your browser.
Settings
PJP PowerShares Dynamic Pharmaceuticals ETF daily Stock Chart
PJP [NYSE]
PowerShares Dynamic Pharmaceuticals ETF
Index- P/E- EPS (ttm)- Insider Own- Shs Outstand- Perf Week-1.35%
Market Cap- Forward P/E- EPS next Y- Insider Trans- Shs Float- Perf Month1.25%
Income- PEG- EPS next Q- Inst Own- Short Float- Perf Quarter7.03%
Sales- P/S- EPS this Y- Inst Trans- Short Ratio0.06 Perf Half Y0.73%
Book/sh- P/B- EPS next Y- ROA- Target Price- Perf Year-9.06%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range53.32 - 68.83 Perf YTD5.56%
Dividend0.53 P/FCF- EPS past 5Y- ROI- 52W High-14.12% Beta-
Dividend %0.90% Quick Ratio- Sales past 5Y- Gross Margin- 52W Low10.85% ATR0.68
Employees- Current Ratio- Sales Q/Q- Oper. Margin- RSI (14)45.91 Volatility0.90% 1.07%
OptionableYes Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.50 Prev Close59.53
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume95.56K Price59.11
Recom- SMA20-0.18% SMA50-0.85% SMA200-1.89% Volume47,687 Change-0.71%
Apr-20-17 05:05PM  Johnson & Johnsons 1Q17 Segment-by-Segment Performance Market Realist
Apr-13-17 04:35PM  Johnson & Johnsons 1Q17 Estimates: Pharmaceuticals Segment Market Realist
Apr-11-17 07:36AM  Analyzing the Performance of Abbott Laboratories in 1Q17 Market Realist
Apr-07-17 06:59PM  ETF Flyers: Pharmaceuticals Barrons.com
03:05PM  Performance of Merck & Co. Stock in 1Q17 Market Realist
Apr-04-17 10:36AM  These Key Product Developments Could Help Pfizer Market Realist
10:36AM  These Key Product Developments Could Help Pfizer
Apr-03-17 10:37AM  Recent Developments at Eli Lilly Market Realist
10:37AM  Recent Developments at Eli Lilly
Mar-30-17 09:08AM  How Eli Lillys Business Segments Performed in 2016 Market Realist
09:08AM  How Eli Lillys Business Segments Performed in 2016
Mar-24-17 10:35AM  Bausch & Lomb Continues to be Key Growth Driver for Valeant Market Realist
10:35AM  Bausch & Lomb Continues to be Key Growth Driver for Valeant
Mar-23-17 09:06AM  New Product Launches May Boost Valeants Dermatology Revenue Market Realist
09:06AM  New Product Launches May Boost Valeants Dermatology Revenue
Mar-22-17 10:36AM  Relistor May Be Solid Growth Opportunity for Valeant in 2017 Market Realist
10:36AM  Relistor May Be Solid Growth Opportunity for Valeant in 2017
Mar-20-17 10:22AM  Trump, Biogen and Amgen Hammer Healthcare ETFs Zacks
10:22AM  Trump, Biogen and Amgen Hammer Healthcare ETFs
Mar-15-17 04:33PM  Should You Buy Pharma ETFs Now? Zacks
04:33PM  Should You Buy Pharma ETFs Now?
03:48PM  [$$] Drug Stocks Look Ready To Move Higher Barrons.com
03:48PM  [$$] Drug Stocks Look Ready To Move Higher at Barrons.com
Mar-09-17 04:09AM  Trumps Obamacare Lite presents opportunities and perils for investors at MarketWatch
Mar-08-17 10:07AM  Trump Tweet on Drug Pricing Hits Biotech and Pharma ETFs
Mar-03-17 03:35PM  How Mylans Europe Segment Performed
Mar-01-17 08:59AM  Hit ETFs & Stocks from the Top Sector of February
Feb-28-17 09:06AM  Eli Lilly & Co.s Recent Developments
Feb-22-17 10:37AM  Keytruda: Merck & Co.s Immuno-Oncology Blockbuster Drug
Feb-09-17 08:00AM  Trending: Financials Trade Sideways as Trump Prepares Dodd-Frank Rollback
Feb-06-17 09:55AM  Q4 Earnings Faring Well for Pharma ETFs
Feb-01-17 09:06AM  Changes in Bristol-Myers Squibbs 4Q16 Profitability
Jan-25-17 12:05PM  Why Eli Lilly Expects to See Revenue Growth in 4Q16
Jan-19-17 04:06PM  What Lies Ahead for Pharma ETFs?
08:00AM  Trending: Pound Gains as Theresa May Lays out Brexit Plan
Jan-13-17 07:36AM  Mylans Profit Margins: What Made Them Change?
Jan-12-17 07:37AM  Understanding Mylans Revenues
Jan-03-17 07:36AM  Harvoni: Gilead Sciences Blockbuster HCV Drug
Dec-12-16 11:06AM  How Could Pfizer Drive Growth for Ibrance?
Dec-07-16 09:44AM  Pisani: Trump rally is evolving
Dec-02-16 04:05PM  Two Nano-Cap Pharma Stocks To Watch Right Now at Insider Monkey
Dec-01-16 10:05AM  Understanding Mercks Most Recent Product Developments
08:05AM  How Baxter Continues to Contribute to Patient Care
Nov-30-16 08:05AM  Steady Rise: Allergans International Segment in 3Q16
Nov-29-16 11:04AM  How Did Gilead Sciencess HCV Business Perform across Geographies?
10:04AM  How Was Bristol-Myers Squibbs Profitability in 3Q16?
Nov-28-16 11:06AM  Gilead Sciences Holds a Broader HIV Portfolio
Nov-25-16 12:04PM  Bristol-Myers Squibb Continues Revenue Growth in 3Q16
08:04AM  Key Investor Insights into Eli Lillys Recent Developments
Nov-23-16 08:04AM  Beyond Oncology: BMYs Eliquis, a Key Growth Driver
Nov-22-16 03:04PM  Understanding Eli Lillys Business Segments by 3Q16 Performance
10:04AM  Inside Bristols Key to Success: Multiple Labels for Opdivo
Nov-18-16 05:04PM  Understanding Bristols Blockbuster: Opdivos Edge over Keytruda
Nov-11-16 05:05PM  November Surprise Rallies Stocks
Nov-10-16 11:26AM  The death of Obamacare will bring new opportunities for investors at MarketWatch
Nov-07-16 11:42AM  Mr. Wonderful's Election Week Trades For A Trump Victory
Nov-01-16 10:04AM  What Will Be Pfizers Profitability in 3Q16?
Oct-20-16 05:48PM  Another Health Care Chart Looks Sick
Oct-19-16 08:06AM  Eli Lillys 3Q16 Estimates: Expect Revenue Growth!
Oct-11-16 11:04AM  BMY Waiting to Enter the First-Line Lung Cancer Space
Oct-07-16 01:16PM  Is the Dividend ETF Bull Run Over?
Oct-05-16 09:42AM  3 ETFs to Buy for a Media Merger Frenzy
Oct-03-16 10:05AM  Why Generic Drugs Will Play a Key Role in the Future
08:05AM  Medicare Negotiations Would Lead to Huge Cost Savings
Sep-30-16 07:04PM  Understanding Mercks Business Segments and Their Revenue Trends
03:04PM  Analyzing Donald Trumps Free-Market Healthcare
01:04PM  How Does Hillary Clinton Plan to Tame Drug Prices?
11:15AM  Generic Drugs Are Crucial in Cost Savings and Accessibility
Sep-26-16 10:05AM  And Then Theres Mylans Specialty Segment, Home of the EpiPen
08:06AM  Whats Driving Growth in Mylans Generics Segment?
Sep-23-16 07:04PM  Generics or Specialty: Which Mylan Segment Is Growing Fastest?
Sep-22-16 10:00AM  Trending on ETFdb.com: Politics and Central Banks Move Markets
Sep-19-16 06:50PM  A Breakdown Here In This Sector Would Not Be Healthy
Sep-01-16 11:04AM  How Are Eli Lillys Business Segments Performing?
Aug-31-16 10:58AM  Biotech Leads the Way in Health Care Stocks to Boost 401(k) Returns
08:04AM  Franchises that Drove Allergans International Sales in 2Q
Aug-24-16 10:04AM  Why Did Hormel Foods Increase Its Fiscal 2016 Guidance?
Aug-23-16 09:30AM  The Zacks Analyst Blog Highlights: PureFunds ISE Junior Silver ETF, SPDR S&P Technology Hardware ETF, PowerShares Dynamic Semiconductors ETF, SPDR S&P Health Care Services ETF and PowerShares DWA Utilities Momentum ETF
Aug-04-16 09:47AM  Top Tech ETFs Of 2016
Aug-03-16 09:04AM  Gilead Sciences Continues to Focus on Improving Care for HCV Patients
Aug-02-16 09:04AM  How Eli Lillys Business Segment Performed in 2Q16
Jul-27-16 11:57AM  This Seasonal ETF Is Ripe For The Pickin' This Summer
Jul-25-16 02:24PM  Bristol-Myers Squibbs 2Q16 Estimates: Expect Growth!
11:04AM  How Did JNJs Medical Devices Segment Perform in 2Q16?
09:20AM  A Consumer Staples ETF To Feast On
Jul-23-16 12:00PM  Restaurants Reflect Consumption Trends (Literally)
Jul-20-16 01:05PM  Why Does Ligand Pharmaceuticals Have Such an Attractive Margin?
Jul-19-16 04:35PM  What Lilly Expects for Revenue Growth in 2Q16
Jul-18-16 09:08AM  Ligand Pharmaceuticalss Portfolio Pyramid as Its Valuation Catalyst
Jul-14-16 01:11PM  Understanding Ligand Pharmaceuticalss PE Multiple
Jul-13-16 11:04AM  How Will Recent Developments Affect Allergan?
Jul-12-16 08:05PM  How Did Allergans Anda Distribution Segment Perform?
05:05PM  Why Are So Many Analysts Rating B&G Foods a Hold?
Jun-29-16 10:59AM  Why Did Cal-Maine Shares Fall 23% in the Last 3 Months?
Jun-28-16 09:07AM  Mylans Profits: Can You Expect Changes?
Jun-24-16 01:15PM  Why Is Mylans Valuation so Low? Our Diagnosis
May-11-16 06:05AM  Hain Celestial Traded above Key Moving Averages
May-07-16 10:01AM  Mudslinging Over Valeant Pharmaceuticals
May-05-16 11:00AM  Trending on ETFdb.com: Central Bank Inaction Moves Markets
May-04-16 09:00AM  Finding Pharmaceuticals ETFs With Rebound Potential
The investment seeks investment results that generally correspond (before fees and expenses) to the price and yield of the Dynamic Pharmaceutical IntellidexSM Index. The fund generally will invest at least 90% of its total assets in common stocks of pharmaceutical companies that comprise the underlying intellidex. The underlying intellidex was composed of common stocks of 23 U.S. pharmaceuticals companies. These companies are engaged principally in the research, development, manufacture, sale or distribution of pharmaceuticals and drugs of all types. The fund is non-diversified.